Advances in the treatment of type 2 diabetes: impact of dulaglutide

Angela M Thompson, Jennifer M TrujilloDepartment of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA Abstract: The purpose of this review is to provide a review of current data of the most recently approved glucagon-like peptide (GLP)-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thompson AM, Trujillo JM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	dulaglutide GLP-1 receptor agonist T2D Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/6444278919ab434dabfaf41f9289d9d9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6444278919ab434dabfaf41f9289d9d9
record_format	dspace
spelling	oai:doaj.org-article:6444278919ab434dabfaf41f9289d9d92021-12-02T07:29:14ZAdvances in the treatment of type 2 diabetes: impact of dulaglutide1178-7007https://doaj.org/article/6444278919ab434dabfaf41f9289d9d92016-05-01T00:00:00Zhttps://www.dovepress.com/advances-in-the-treatment-of-type-2-diabetes-impact-of-dulaglutide-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Angela M Thompson, Jennifer M TrujilloDepartment of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA Abstract: The purpose of this review is to provide a review of current data of the most recently approved glucagon-like peptide (GLP)-1-receptor agonist, dulaglutide, in the treatment of type 2 diabetes. To complete this, a PubMed search was performed to identify manuscripts published from 1947 to July 2015. The search terms “Trulicity”, “dulaglutide”, and “LY2189265” were utilized, and publications were included if they evaluated the pharmacology, pharmacokinetics, efficacy, safety, or patient-reported outcomes of dulaglutide. Dulaglutide is a GLP-1 receptor agonist that mimics endogenous GLP-1, the hormone produced in response to food intake. Modifications have been made to the molecule to delay breakdown and allow for once-weekly dosing. Dulaglutide has been studied as monotherapy and in combination with several agents, including metformin, glimepiride, pioglitazone, and insulin lispro. Dulaglutide has demonstrated superior efficacy compared to placebo, metformin, insulin glargine, sitagliptin, and twice-daily exenatide. It was found to be noninferior to liraglutide. The most common adverse effects in clinical studies were gastrointestinal-related adverse events, and patient satisfaction was high with the use of dulaglutide. Dulaglutide is an appealing option for the treatment of type 2 diabetes, based on its once-weekly dosing, A1c lowering comparable to liraglutide, weight reduction comparable to exenatide, and a similar adverse-effect profile to other GLP-1 receptor agonists. Keywords: dulaglutide, GLP-1 receptor agonist, T2DThompson AMTrujillo JMDove Medical PressarticledulaglutideGLP-1 receptor agonistT2DSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 125-136 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	dulaglutide GLP-1 receptor agonist T2D Specialties of internal medicine RC581-951
spellingShingle	dulaglutide GLP-1 receptor agonist T2D Specialties of internal medicine RC581-951 Thompson AM Trujillo JM Advances in the treatment of type 2 diabetes: impact of dulaglutide
description	Angela M Thompson, Jennifer M TrujilloDepartment of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA Abstract: The purpose of this review is to provide a review of current data of the most recently approved glucagon-like peptide (GLP)-1-receptor agonist, dulaglutide, in the treatment of type 2 diabetes. To complete this, a PubMed search was performed to identify manuscripts published from 1947 to July 2015. The search terms “Trulicity”, “dulaglutide”, and “LY2189265” were utilized, and publications were included if they evaluated the pharmacology, pharmacokinetics, efficacy, safety, or patient-reported outcomes of dulaglutide. Dulaglutide is a GLP-1 receptor agonist that mimics endogenous GLP-1, the hormone produced in response to food intake. Modifications have been made to the molecule to delay breakdown and allow for once-weekly dosing. Dulaglutide has been studied as monotherapy and in combination with several agents, including metformin, glimepiride, pioglitazone, and insulin lispro. Dulaglutide has demonstrated superior efficacy compared to placebo, metformin, insulin glargine, sitagliptin, and twice-daily exenatide. It was found to be noninferior to liraglutide. The most common adverse effects in clinical studies were gastrointestinal-related adverse events, and patient satisfaction was high with the use of dulaglutide. Dulaglutide is an appealing option for the treatment of type 2 diabetes, based on its once-weekly dosing, A1c lowering comparable to liraglutide, weight reduction comparable to exenatide, and a similar adverse-effect profile to other GLP-1 receptor agonists. Keywords: dulaglutide, GLP-1 receptor agonist, T2D
format	article
author	Thompson AM Trujillo JM
author_facet	Thompson AM Trujillo JM
author_sort	Thompson AM
title	Advances in the treatment of type 2 diabetes: impact of dulaglutide
title_short	Advances in the treatment of type 2 diabetes: impact of dulaglutide
title_full	Advances in the treatment of type 2 diabetes: impact of dulaglutide
title_fullStr	Advances in the treatment of type 2 diabetes: impact of dulaglutide
title_full_unstemmed	Advances in the treatment of type 2 diabetes: impact of dulaglutide
title_sort	advances in the treatment of type 2 diabetes: impact of dulaglutide
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/6444278919ab434dabfaf41f9289d9d9
work_keys_str_mv	AT thompsonam advancesinthetreatmentoftype2diabetesimpactofdulaglutide AT trujillojm advancesinthetreatmentoftype2diabetesimpactofdulaglutide
_version_	1718399405169573888

Advances in the treatment of type 2 diabetes: impact of dulaglutide

Ejemplares similares